Trial completion date • Trial primary completion date
|
HLA-A (Major Histocompatibility Complex, Class I, A) • MSLN (Mesothelin) • CTAG1B (Cancer/testis antigen 1B)
|
MSLN positive • HLA-A positive
|
multi-target gene-modified CAR-T/TCR-T cell immunotherapy